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Abstract
We performed gene–gene interaction analysis, with HLA-DRB1 shared epitope (SE) alleles for 195
SNPs within immunologically important MAP2K, MAP3K and MAP4K gene families, in 2010
rheumatoid arthritis (RA) patients and 2280 healthy controls. We found a significant statistical
interaction for rs10468473 with SE alleles in autoantibody-positive RA. Individuals heterozygous
for rs10468473 demonstrated higher expression of total MAP2K4 mRNA in blood, compared to
A-allele homozygous. We discovered a novel, putatively translated, “cassette exon” RNA splice
form of MAP2K4, differentially expressed in peripheral blood mononuclear cells from 88 RA cases
and controls. Within the group of RA patients, we observed a correlation of MAP2K4 isoform
expression with carried SE alleles, autoantibody, and rheumatoid factor profiles. TNF-dependent
modulation of isoform expression pattern was detected in the Jurkat cell line. Our data suggest a
genetic interaction between MAP2K4 and HLA-DRB1, and the importance of rs10468473 and
MAP2K4 splice variants in the development of autoantibody-positive RA.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t of Medicine Solna, Karolinska In
1775562.
sky@ki.se (K. Shchetynsky).
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Rheumatoid arthritis (RA) is a common autoimmune disease,
characterized by chronic inflammation and severe impairment
of the joints, that affects about 1% of the world population.stit
isHLA-DRB1 shared epitope (SE) alleles are the major genetic
risk factors for this condition [1]. RA patients positive for
anti-citrullinated protein antibodies (ACPAs) constitute two
thirds of all RA cases and represent a group with higher disease
severity. Along with rheumatoid factor (RF) and the number ofutet, Rheumatology Unit, CMM:L8:04, Karolinska University Hospital,
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20 K. Shchetynsky et al.carried SE alleles, ACPA-positivity is one of the major factors
determining poor prognosis for RA development [2,3].
TNF blockade is an efficient treatment of RA and a
significant fraction of the patient population demonstrates
good or very good response to this medicine. However, not all
patients achieve full remission and some side effects are
observed. One of the recent developments in biological
therapy for RA is targeting mitogen-activated protein kinases
(MAPKs), in particular p38 and JNK. MAPKs are considered to
be among the key inflammatory mediators for autoimmune
diseases due to their involvement in the regulation of immune
response to stress stimuli [4]. Both JNK and p38 regulate
interferon-γ-mediated gene expression, however, p38 acti-
vates genes related to innate immunity, while JNK acts on
genes connected to antigen presentation [5,6]. MAPKs
mediate TNF-receptor signaling and are important regulators
of pro-inflammatory cytokine production, which is considered
to be a major pathogenic factor in RA [6].
However, clinical trials with direct inhibitors of MAPKs were
characterized by limited efficacy, partially due to side effects.
It has been suggested that focusing on targets upstream of the
p38 and JNK pathway may provide fine regulation of down-
stream events, resulting in more advantageous clinical strate-
gies [4].
Genetic associations with complex diseases, e.g. RA,
exhibit a moderate to low effect on incidence risk. Recently,
we have demonstrated that interaction between genes may
explain risk more successfully than the independent influence
from separate variations [7,8]. Analysis of gene–gene and
gene–environment interactions, combined with existing
biological knowledge, has been described as a useful tool in
discerning disease-associated genetic loci [9].
In this work, we assess the relevance of candidate genetic
loci involved in MAPK signaling to rheumatoid arthritis, by
investigating gene–gene interaction between loci that encode
knownMAP2Ks, MAP3Ks and MAP4Ks withHLA-DRB1 SE alleles in
two independent cohorts. Based on our findings, we proceeded
to look at the association of transcript-specific expression of
MAP2K4 with the distinctive phenotype of ACPA-positive RA in
mRNA from the peripheral blood of RA patients and healthy
individuals. Finally, to address the potential role of MAP2K4
transcripts in RA-related inflammatory processes, we investi-
gated the response of MAP2K4 transcript expression to TNF
stimulation in lymphatic cell-lines.2. Materials and methods
2.1. Patients and controls
The interaction studywas based on the Swedish Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) cohort (1921 RA
cases and 1079 healthy controls of Caucasian ethnicity), and
was performed on data available from our genome-wide
association analysis [11]. Initially, the number of ACPA-
positive patients in the RA group constituted 1149 individuals.
To reach higher numbers in groups with underrepresented
genotypes, the number of ACPA-positive RA patients was
increased to 2010 and the number of healthy controls was
increased to 2280. The expansion of the EIRA cohort was done in
full adherence to initial selection criteria.The RNA expression experiments utilized PBMC-samples
from 44 RA patients and 44 controls, and an independent
source of whole blood samples from 80 RA patients and 80
controls from the Swedish population; controls were selected
with consideration to gender, age and ethnicity for the patient
group. RA patients were selected at the Rheumatology Clinic at
Karolinska University Hospital on two occasions, and all
correspond to ACR 1987 criteria for rheumatoid arthritis [10].
Subjects with any significant health problem, other than
rheumatoid arthritis, and non-RA related laboratory abnormal-
ities were not included. Information about anti-citrullinated
protein antibody (ACPA) status, smoking habits and medication
(for RA patients) was obtained from medical records. Informed
consent was obtained from all participants in all cohorts, in
compliance with the latest version of the Helsinki Declaration.
Regional ethical committees at all sites have approved the
study.
2.2. Genotyping
Genotyping for the MAP loci was performed by Illumina 300K
chip in our previous GWAS study [11]. Additionally, we
performed genotyping of rs10468473 using TaqMan allelic
discrimination assay (Life Technologies, Europe) according to
the manufacturer's instructions. HLA-DRB1 data was obtained
and reported for this cohort previously [12]. The validation of
genotyping data for rs10468473 demonstrated 99.8% consis-
tency with GWAS data.
The North-American Rheumatoid Arthritis Cohort (NARAC)
dataset was genotyped on the Illumina InfiniumHumanHap550
platform for 545,080 SNPs [11].
2.3. RNA extraction and cDNA synthesis
The RNA extraction was performed either from whole blood or
from PBMC samples in two independent materials. For whole
blood samples (80 RA patients and 80 healthy controls), blood
was collected into PAXgene Blood RNA Tubes and total RNA
was extracted with the PAXgene Blood RNA kit (PreAnalytiX,
Feldbachstrasse, Switzerland) according to themanufacturer's
protocol. For PBMC (44 RA patients and 44 healthy controls),
blood was collected in sodium citrate vacuum tubes and PBMC
were isolated by Ficoll-Paque (GE Healthcare Life Sciences,
Uppsala, Sweden) separation.
For PBMC, after incubation, 5 × 105 cells of each sample
were harvested and lysed with RLT buffer from the RNA
Miniprep kit (QIAGEN Hilden, Germany). Subsequently, RNA
was extracted, with RNeasy Mini (QIAGEN, Hilden, Germany).
An additional step of DNase digestion was performed with
RNase-Free DNase Set (QIAGEN). Samples were stored at −
80 °C prior to cDNA synthesis, which was performed with an
iScript cDNA synthesis kit following the manufacturer's protocol
(Bio-Rad, Hercules, CA, USA).
2.4. Detection of splicing variants by generic PCR
To cover the canonical sequence of the catalytic domain of
MAP2K4, the following primers were used: Forward 5′-CTGAG
AACACACAGCATTGAGTC-3′ and Reverse 5′-CACAAAAGAG
CAGGATGAGGTC-3′. The specific primers for splicing isoform
MAP2K4_v1 with skipped exon 5 were created to span the
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AAGCACTAAA-3′; Reverse 5′-CAGACATCAGAGCGGACATC-3′).
Each primer system was used in a separate experiment with
various cDNA templates. The enzyme used for PCR reaction
was AmpliTaq Gold, together with GeneAmp dNTP Mix
(Applied Biosystems, Branchburg, NJ, USA). Evaluation of
PCR products was performed by PAGE on NOVEX TBE pre-cast
gradient 4–12% gels (Invitrogen, Life Technologies Europe),
stained with 3/10,000 GelRed (Biotium Inc.). Digitalization
was done with Gel Doc XR+ Imaging System (Bio-Rad).2.5. Quantitative PCR
Pre-made, real-time gene expression assay Hs00387426_m1
(Applied Biosystems, Life Technologies, Europe), with probe
spanning exons 3–4 of the original sequence was used for
general expression readout from the MAP2K4 locus.
Two custom TaqMan assays from Applied Biosystems, with
similar amplicon sizes, were designed to probe the canonical
form of MAP2K4_v1 (Forward 5′-AGTGATTGCCCATACATTGTT
CAGT-3′; Reverse 5′-CGAGGTAGACATGAGTTCCATACAG-3′; Re-
porter 5′-FAM*-CCAACAGTCACCCTCTCTG-NFQ**-3′) and spicing
isoform MAP2K4_v2 with skipped exon 5 (Forward 5′-AGTGAT
TGCCCATACATTGTTCAGT-3′; Reverse 5-TGGAAGGTTTGATAT
CTCTGTGAATAATTTTCA-3 Reporter 5′-FAM*-TAGTGCTTTCACA
GTCTCTC-NFQ**-3′). For primer design, the on-line Custom
TaqMan Assay Design Tool from Applied Biosystems was used.
The experiments were done at least in triplicate. Three
non-template controls were included in each experiment.
Expression measurements were made using the delta–delta
relative quantification method (ΔΔ Cycle threshold) with an ABI
7900HT Sequence Detector and Sequence Detection System
Software 2.4. The ZNF592 gene was used as an endogenous
reference control, as previously described [13]. The mean ΔCt
values for controls were used as a calibrator.2.6. Transfection and stimulations
Transfection plasmids E5 and noE5 were based on cDNA
sequences of the canonical MAP2K4 and the putative variant
(lacking exon 5) respectively — inserted into a PrecisionShuttle
mammalian vector with N-terminal His-DDK tag (PS100018,
OriGene Technologies Inc., MD, USA). Both constructs were
manufactured by, and purchased from, Blue Heron Biotech LLC,
WA, USA.
For transfection, HEK293 cells (2×105 cells/well) were
seeded in a 6-well tissue culture plate. The day after, cells
were transfected with 2 μg of E5, noE5 or pcDNA empty
vector using GeneJuice transfection reagent (Merck
Millipore, Sweden), according to themanufacturer's instruction.
The cells were collected 24 h after transfection by scraping
from the culture plates and lysed for Western blotting.
All the cell lines were purchased from ATCC and kept
in Dulbecco's modified medium or RPMI-1640 medium –
supplementedwith 10% fetal bovine serum (Gibco, Life Techno-
logies, Sweden), L-glutamine, and penicillin/streptomycin – in
a 37 °C incubator with 5% CO2. The authenticity of the cell
lines was verified using genotyping.
TNF was purchased from Peprotech, Scandinavia.2.7. Western blotting
To identify MAP2K4 isoforms we used the commercial
antibodies for a canonical MAP2K4 protein (Santa Cruz, USA).
By comparison of antibody specificity using protein-BLAST, we
selected a monoclonal antibody against the C-terminus of the
protein, which was predicted as a common domain for known
and new isoforms.
Cell lysates were prepared in 50 mM Tris–HCl, pH 7.4, 1%
NP40, 150 mM NaCl, 1 mM EDTA, 1% glycerol, and protease
inhibitor cocktail (Roche Diagnostics GmbH, Mannheim,
Germany). 20 μg of total protein was separated by 4%–12%
PAGE (XCell SureLock™ Mini-Cell Electrophoresis System,
Invitrogen, Sweden) and transferred to PVDF-membranes
using the iBlot® dry transfer system (Invitrogen by Life
Technologies, Sweden). The membranes were blocked in 5%
milk in PBS-Tween20 (1× PBS plus 0.1% Tween-20). Blocking
was followed by incubation with: primary antibody at +4 °C
overnight (mouse monoclonal anti-MAP2K4: Santa Cruz,
sc-166168), or 1 h at room temperature (GAPDH: #AB9485,
Abcam); and secondary antibody (HRP-conjugated anti-mouse
from Rockland, #20789) for 1 h at room temperature. The
PVDF membranes were developed using Western Lightning–
ECL from PerkinElmer, Sweden AB. Images were obtained with
a LAS-1000 from Fujifilm. Molecular weight standards were:
Biotinylated Protein Ladder (Cell Signaling Technology®, In
Vitro AB, Sweden) and Spectra TM Multicolor Broad Range
Protein Ladder (Fermentas, ThermoFisher Scientific, Sweden).2.8. Statistics
The interaction was tested for 195 SNPs from the 12 loci for
MAPKK, MAPKKKs and JNK1 against HLA-DRB1 SE alleles
(DRB1*01, *04 and *10). The calculation of interaction was
performed with an algorithm, based on R programming
language [14]. To assess genetic interaction, relative exces-
sive risk (departure from additivity) was calculated for the
group of individuals, carrying both prospective risk markers,
and represented as the attributable proportion of risk due to
interaction (AP) with 95% CI. The cohort was additionally
stratified for ACPA status. Gender was treated as a potential
confounder. Bonferroni correction of p-values for AP was used
with study-wide threshold for the significance of 2.6 × 10−4.
All SNPs were tested for interaction with SE alleles using the
binary dominant/recessive model.
Quantitative expression data was analyzed by the
non-parametric Mann–Whitney U (2 groups) or Kruskal–Wallis
(3 groups) tests. The threshold for significance was p = 0.05.3. Results
3.1. SNP rs10468473 from MAP2K4 is in statistical
interaction with HLA-DRB1 in ACPA-positive RA
We performed interaction analysis on pairwise combinations of
HLA-DRB1 SE alleles and 195 SNPs from 12 genetic loci encoding
known MAP2K, MAP3Ks and MAP4Ks upstream of JNK1 and
p38 (including JNK1), in 1921 RA cases and 1079 healthy
controls (EIRA cohort). Our data indicate that a single SNP,
rs10468473, is in a relatively strong interaction withHLA-DRB1
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p = 4.4 × 10−6, 95% CI [0.51–1.0]) (Supplementary Fig. S1,
Supplementary Datasheet SD1).We found little evidence for the
interaction of HLA-DRB1 SE alleles with other genetic variations
in MAP2K and MAP3K related loci, after correction for multiple
comparisons had been performed. The SNP rs10468473 A/G is
located 21 kb downstream of the MAP2K4 gene, with minor
allelic frequency of 0.097 in our healthy control population
(HapMap-CEU MAF 0.093).
To improve the representation of the individuals, positive
exclusively for rs10468473 risk allele in our interaction analysis,
we performed additional genotyping for this SNP in 861 RA
patients and 1200 controls from EIRA study (not previously
included in GWAS). In the extended cohort, rs10468473 from
the MAP2K4 locus remained in significant interaction with SE
(AP = 0.434, p = 0.041, 95% CI [0.018–0.85]) (Fig. 1). These
results imply that the MAP2K4 polymorphism and SE alleles are
associated with a non-linear increase in risk for ACPA-positive
RA. Additionally, we performed haplotype analysis for all 22
GWAS SNPs from the MAP2K4 locus in our cohort of 1167
Swedish Caucasians, but could not observe a strong linkage of
rs10468473 to other MAP2K4 SNPs (Supplementary Fig. S2).
3.2. Association of rs10468473 genotype with
MAP2K4 expression
To find possible mechanisms, explaining the risk association
of genetic variation in the MAP2K4 locus, we investigated
the allelic expression of the MAP2K4 gene in mRNA from
peripheral blood mononuclear cells of 44 RA patients and 44
matched controls with known rs10468473 genotype. Our
data showed significantly elevated MAP2K4 expression in RA
patients heterozygous for rs10468473, compared to individuals
homozygous for A allele (Fig. 2A). This difference in MAP2K4
expression between different rs10468473-genotypes could not
be observed in healthy controls (Fig. 2B). Due to the low
frequency of theminor allele, individuals with the homozygotic
state of the G were not present in our expression panel.Figure 1 SNP rs10468473 from the MAP2K4 locus, when combined
ACPA-positive RA. Representative data shown for extended EIRA co
proportion (AP). The analysis was based on 2010 ACPA-positive case
for carriers of different risk genotypes: SE — individuals with shared
10468473_A risk genotype; −rs10468473_A + SE— individuals with both
unaffected individuals; the area of the squares represents the log-size o3.3. MAP2K4 gene is expressed as alternative
putatively protein-coding transcripts
We performed an exploratory study by using generic PCR to
identify a spectrum of MAP2K4 mRNA products, detectable in
PBMC.We identified a series of transcripts with altered exonic
composition, and a prevalence of “cassette-exon”-type
splicing events in the coding part of the Serine/Threonine
protein kinase catalytic domain (Fig. 3A) Specifically, exon 5
skipping had been reported previously for various transcripts
of human (ENST00000538465; ENST00000538465) and mouse
(ENSMUST00000125598) origin, and was featured in our mate-
rial (Fig. 3B). In a screening in mRNA from the PBMC, we could
observe and sequence transcripts with exon 5 skipping in mRNA
from 19/20 RA patients and 20/20 controls (Supplementary
Fig. S3).
Importantly, the absence of exon 5 alone does not result
in a shift of open reading frame. To assess the possibility of
translation forMAP2K4 transcript with skipped exon 5 (assigned
as V2), we transfected HEK293 cells with V1- and V2-containing
plasmids. Both V1 and V2 transfection products could be
detected by using commercially available mouse monoclonal
anti-MAP2K4 in lysates of transfected HEK293 cells. Proteins
with similar molecular weight were also detectable in non-
transfected T-lymphocyte cell lines by Western Blot, using
commercially available mouse monoclonal anti-MAP2K4 against
the C-terminal part of MAP2K4 (Fig. 3C).3.4. Differential expression of MAP2K4 transcripts
reflects genetic and phenotypic features of RA
We investigated the production of MAP2K4 transcript with
skipped exon 5 (assigned as MAP2K4_V2) in relation to the
expression of canonic full isoform (assigned as MAP2K4_V1),
in PBMC from 38 RA cases and 43 controls, using probe-based
RT-qPCR with probes spanning exonic junctions 4/5 and 4/6,
respectively. When taken as a ratio (V2/V1), the expressionwith SE, provides a significant, non-additive increase in risk for
hort. The statistical interaction is represented by attributable
s and 2280 healthy controls. Data presented as relative risk (RR)
epitope risk genotype; rs10468473 — individuals with MAP2K4 rs
MAP2K4 rs1046847 and SE risk genotypes; reference line (dashed)—
f the genotype group; whiskers show RR confidence intervals.
Figure 2 rs10468473 genotype correlates with MAP2K4 gene expression in RA patients. A. The expression ofMAP2K4 gene is significantly
higher in PBMC of 13 RA patients, with a heterozygous G/A genotype for rs10468473, compared to 22 patients homozygous for A allele
(p = 0.045). B. In healthy controls, no significant change in MAP2K4 expression was observed between individuals with G/A (n = 4)
and A/A (n = 32) rs10468473 genotypes. Shown are the relative quantification values (RQ) for MAP2K4 expression in PBMC of RA
patients and healthy controls with known rs10468473 genotype. The expression of MAP2K4 was measured by TaqMan qPCR using
predesigned gene-expression assay Hs00387426_m1, spanning exons 3–4 of the original sequence. Mann–Whitney U test with a
significance threshold of p = 0.05 was used for statistical analysis.
23MAP2K4 gene-gene interaction and RNA splicing profiles in RAof the transcripts was significantly different for RA patient and
healthy control groups (Fig. 4A). The transcript ratio is primarily
influenced by the increased expression of MAP2K4_V1 in RA
patients (Supplementary Fig. S4A–B). We replicated these
findings in an independent material of whole blood mRNA from
80 RA patients and 80 healthy individuals (data not shown).
In RA patients, we identified a significant correlation and a
dosage effect between the number of carried SE alleles and the
MAP2K4 V2/V1 expression ratio (Fig. 4B). Within the same
group, we could also observe a correlation between the
MAP2K4 variant expression ratio and RA-related serological
factors, i.e. the presence of ACPA (measured as anti-CCP-
antibodies) and presence of rheumatoid factor (RF) (Fig. 4C, D).
These differences in V2/V1 expression ratio were consistently
correlatedwith the increased expression ofMAP2K4_V2 isoform
in groups of individuals positive for SE-alleles and serological
markers (Supplementary Fig. S5A–B and C–D, respectively).
There was no significant connection between smoking habits
and the expression ratio ofMAP2K4 variants within the group of
RA patients in our study (data not shown).3.5. MAP2K4 isoforms are differentially expressed
in lymphatic cell-lines under TNF stimulation
We studied the effect of TNF stimulation on the transcript
expression ratio of MAP2K4 in lymphatic and myeloid cell-lines.
The expression of MAP2K4 V1/V2 was measured at four
different time points in Jurkat, Raji, and U937 cell lines treated
with TNF. The transcripts of MAP2K4 were differentiallyexpressed in T-cell-like Jurkat cell-line at 24 h of stimulation
(Fig. 5A). There was no significant difference in transcript ratio
for Raji and U937 (Fig. 5B, C).4. Discussion
Our data suggest that the MAP2K4 gene is an important
candidate gene for RA that was overlooked in GWAS studies,
due to the fact that it only elevates risk for disease in
combination with HLA-DRB1 SE alleles. The differential
expression of mRNA possibly points to the important contribu-
tion of MAP2K4 splicing isoforms for disease development,
which may be specific for the function of this kinase in T-cells.
Therefore, the interaction between HLA-DRB1 SE alleles and
MAP2K4 alleles, observed in our data, could arise due to
mechanisms downstream of antigen presentation.
Recently, studies of gene–gene interaction effects have
proven to be instrumental in understanding gene function
[15]. Although straightforward functional interpretation of
interaction between genes can be challenging, incorporating
prior data on functional pathways and molecular biology
could be an effective strategy of improving and expanding
the applicability of gene–gene interaction studies [16].
The results of our study, with analysis of genetic variations
in MAPKK and MAPKKK related loci, imply an interaction
between a single member of the MAP signaling pathway,
MAP2K4, andHLA-DRB1 SE loci, that may contribute to the risk
of autoantibody-positive rheumatoid arthritis. Significant
interaction between MAP2K4 and SE in ACPA-positive RA was
Figure 3 Transcript diversity from the MAP2K4 gene. A. The schematic of the MAP2K4 transcripts illustrates structural difference
between the canonical and the alternatively spliced forms, with a black bracket over the amplification area. Exons 3–11 form the
translated catalytic domain of MAP2K4 protein (gray rectangle). Exon junctions targeted with custom TaqMan probes MAP2K4_v1 and
MAP2K4_v2 are marked with black and gray asterisks respectively. “†” marks position of the TaqMan probe in commercial assay
Hs00387426_m1. B. A “skipped-exon” variant MAP2K4 was characterized in whole-blood mRNA. Shown are the PCR amplification
spanning exons 3–11 of the original MAP2K4 sequence. The canonical MAP2K4 transcript (black arrow) and a “skipped exon” splice
form (gray arrow) were confirmed through sequencing. C. MAP2K4 NoE5 protein isoform can be detected with monoclonal
anti-MAP2K4 G6 and rabbit polyclonal G6 IgGs in lysates of in HEK293 cells, transfected with cDNA of NoE5 splicing variant of MAP2K4.
The produced band is similar to the lower molecular weight product in 2-product pattern, detectable with the same antibody in both
HEK293 cells, transfected with canonical MAP2K4 cDNA and untransfected Jurkat cells (right). Full-MAP2K4-transfected and
untransfected HEK293 also exhibit lower molecular weight products that are not present in the MAP2K4 NoE5 HEK293 transfection.
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extended with additional rs10468473 genotyping data. These
results constitute an interaction profile that is connected to
increased risk of ACPA-positive rheumatoid arthritis and can be
helpful for clinical prediction in the future. Based on the
interaction of MAP2K4 SNP with the major risk factor for RA, it
is possible thatMAP2K4 plays a role in RA pathogenesis only in a
specific subgroup of individuals with HLA-DRB1 SE alleles.
Notably, rs10468473 MAF is higher in Asian populations than in
Caucasians. It would be interesting to investigate found effects
in relation to RA in these populations.
Importantly, we observed association of the rs10468473
genotype with MAP2K4 mRNA expression, in our material of
PBMC from RA patients. This allows us to assume that
rs10468473, or other SNPs in high linkage disequilibrium (LD)with it, is potentially related to the regulation of expression in
the MAP2K4 locus, and could be involved in inflammatory
responses in RA.
To achieve the required variety of functions, almost all
immunologically relevant genes undergo alternative splicing
[17]. It has been suggested that the balance in production of
alternatively-spliced gene transcripts could be relevant for
disease progression and, hence, for the development of
potential therapies [18]. Additionally, the isoforms of proteins
with a function in immunity, such as CD44, TNFR2, IL-32, and
IL-6R, were also shown to influence antigen processing and
have a clinical relevance for autoimmunity [19–22]. Hytönen
A.-M. et al. have demonstrated that a higher level of soluble
IL-4R isoforms in asthma patients, compared with controls,
has biological consequences [23]. It was also demonstrated
Figure 4 Expression of V1 and V2 mRNA isoforms in PBMC of 38 RA patients and 43 controls. A. An expression ratio for full and
exon-5-deficient MAP2K4 transcripts (V1 and V2 respectively) is significantly different in PBMC samples from healthy controls and RA
patients. Data shown as relative quantification ratio (RQMAP2K4 V2/V1) for 38 RA patients and 43 controls, analyzedwith theMann–Whitney
U test (p b 0.005). B. Within the group of RA patients, MAP2K4 transcripts V1 and V2 were differentially expressed in SE-negative (NO SE),
SE-positive (SE), and double-SE-positive (DOUBLE SE) individuals. Data shown as relative quantification ratio (RQ MAP2K4 V2/V1) for 38 RA
patients, analyzed by Kruskal–Wallis ANOVA (p b 0.001). C. The expression ratio of MAP2K4 transcripts V2/V1 was different in RF-negative
(NO RF) and RF-positive (RF) RA patients. Data shown as relative quantification ratio (RQ MAP2K4 V2/V1) for 38 RA patients, analyzed with
the Mann–Whitney U test (p b 0.05). D. In RA patients, anti-CCP-negative and anti-CCP-positive profiles correlated with MAP2K4 transcript
expression ratio V2/V1. Data shown as relative quantification ratio (RQMAP2K4 V2/V1) for 38 RA patients, analyzed with the Mann–Whitney
U test (p b 0.001).
25MAP2K4 gene-gene interaction and RNA splicing profiles in RAthat the ratio of PTPN22 splice forms is shifted in RA patients,
compared to healthy controls, which can have an influence on
immune response [13].
In this study we characterize splicing events in MAP2K4,
resulting in partial lack of catalytic domain coding sequence.
According to the range of discovered splice variants, spliced-
out exon 5 could be characteristic for several MAP2K4transcripts. Specifically, MAP2K4_V2 could be consistently
identified with a specific primer-set in mRNA from PBMC of RA
patients and controls. The skipping of exon 5 does not introduce
premature translation termination codons within an open
reading frame and could be effectively translated into a protein
product, as confirmed by our transfection experiments in
HEK293. However, it has to be noted that HEK293 cells are
Figure 5 Expression of MAP2K4 isoforms in stimulated Jurkat, U937 and Raji cells. Cells were left untreated (control) or were treated
with 50 ng/ml TNF for the presented time periods. Experiment was repeated in biological triplicates. Data analyzed by TaqMan
quantitative RT-PCR and presented as a relative quantification ratio (RQMAP2K4 V2/V1). The error bars indicate the standard deviation.
26 K. Shchetynsky et al.likely not to have an identical MAP2K4 splicing profile to that of
hematopoietic cells.
The possibility of translated, exon-5 deficient MAP2K4
isoforms is further supported by the existence of a splicing
variant with an in-frame alternative transcription start site in
exon 4, combined with exon 5 skipping, reported in expression
data from 11 normal human tissues in the EASANA Genosplice
micro-array database (TISSUES; GSHG0012237) and a protein-
coding transcript of the same structure, confirmed in mouse
(ENSMUST00000125598). This type of splicing event could
have a distinctive effect on the function of a putative protein
product of MAP2K4, since exon 5 constitutes a part of the
catalytic center of MAP2K4. Currently, further proteomic
analysis is necessary to elucidate the origin and structure of
these protein isoforms, detected in our study with MAP2K4
antibodies against the C-terminal part of the protein.Our results show differential expression of the canonical and
alternatively spliced MAP2K4 mRNAs in RA patients, compared
to healthy controls. In our data, the MAP2K4 V2/V1 expression
ratio also reflects other genetic and phenotypic features of the
disease in the RA group, namely ACPA status, RF positivity, and
number of SE alleles. The decreased V2/V1 ratio in RA patients
could be chiefly attributed to the increased expression of
canonical MAP2K4 transcript, while the correlations with SE
alleles and serological markers within the RA group are driven
by V2 (NoE5).
It has been reported that SNPs located in untranslated
areas may contribute to the regulation of gene splicing [24].
However, we could not see a clear association between the
rs10468473 or 21 other common MAP2K4 SNP genotypes with
the expression of individual splicing variants (canonical and
lacking exon 5) of the MAP2K4 gene. Further work is needed
27MAP2K4 gene-gene interaction and RNA splicing profiles in RAto clarify whether downstream genomic variation directly
influences MAP2K4 expression and transcript abundance,
or represents LD with other unidentified SNPs within the
locus.
TNF signaling leads to the activation of JNK, p38 and ERK
MAPKs [25]. The observed effect of TNF stimulation on the
transcript ratio in our experiments in the Jurkat cell-line, but
not in Raji or U937, may indicate a cell-type specific splicing
profile of MAP2K4 in pro-inflammatory conditions — and a
topic for further analyses of mechanisms of involvement in RA
and development of treatment strategy. This is in line with the
established effect of anti-TNF treatment in RA and suggests
how T-cell specific expression of MAP2K4 isoforms could be
functionally involved in RA pathogenesis through the regula-
tion of proliferation in the T-cell population.
Alternative mRNA transcripts can have a regulatory function
by competing with the canonical transcript and shifting the
amount of the main variant in the total gene output [26]. This
knowledge can support the functional significance of splicing in
MAP2K4 transcripts, even when the translation efficiency for
non-canonical products is lower. It also seems reasonable to
consider the possibility of NMD-subjected transcripts potentially
retaining a mRNA-level regulatory capacity in disease patho-
genesis [27]. It remains to be determined whether, and if so,
how the balance of MAP2K4 splice variants may functionally
affect the activation of downstream JNK and p38 in the
context of autoimmunity. The quantity of an alternative
MAP2K4 isoform could potentially interfere with complex
formation and activation of downstream p38 and JNK
MAPKs. Both JNK and p38 regulate interferon-γ-mediated
gene expression, with p38 activating innate immune genes,
while JNK acts on genes connected to antigen presentation [5].
Moreover, MAPKs are the main regulators of pro-inflammatory
cytokine production, which is considered to be one of themajor
driving factors of RA [6]. If the gene expression of MAP2K4 is
constitutively effected by a specific genotype it could poten-
tially contribute to the development of autoimmunity over
time.
5. Conclusion
In conclusion, we find that rs10468473 affects the expression
of the MAP2K4 gene and is in statistical interaction with
HLA-DRB1 SE alleles in the context of rheumatoid arthritis.
The cassette exon 5 in MAP2K4 transcripts may represent a
functionally and clinically meaningful splicing event that
could potentially have a major impact on protein isoforms of
MAP2K4. This may be a useful finding for risk prediction and
development of potential therapies.
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